GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
February 01, 2024 11:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders
December 06, 2023 09:30 ET
|
GT Biopharma, Inc.
The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma,...
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
December 04, 2023 09:30 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
GT Biopharma Reports Second Quarter 2023 Financial Results
August 07, 2023 09:00 ET
|
GT Biopharma, Inc.
Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and initiate clinical...
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023
August 03, 2023 13:25 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 17:00 ET
|
GT Biopharma, Inc.
Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and GTB-5550, and...
GT Biopharma Names Charles J. Casamento to the Board of Directors
May 04, 2023 09:05 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based...
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 17:00 ET
|
GT Biopharma, Inc.
Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium...
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
February 24, 2023 09:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
February 02, 2023 09:46 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...